Edition:
United Kingdom

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

6.40USD
8 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.40
Open
$6.50
Day's High
$6.55
Day's Low
$6.25
Volume
32,340
Avg. Vol
39,739
52-wk High
$8.20
52-wk Low
$2.05

Summary

Name Age Since Current Position

John Johnson

59 2015 Chairman of the Board

Matthew Pauls

46 2014 Chief Executive Officer, Director

A. Davis

48 2015 Chief Financial Officer

Stephen Long

50 2015 Chief Legal Officer

Robert Lutz

46 2014 Chief Business Officer

Ruth Thieroff-Ekerdt

59 2014 Chief Medical Officer

Richard Kollender

2015 Director

Garheng Kong

41 2015 Director

Marten Steen

39 2014 Director

Hilde Steineger

49 2014 Director

Biographies

Name Description

John Johnson

Mr. John H. Johnson is Chairman of the Board of the company. since March 2015. From January 2012 until August 2014, Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012, he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011, Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008, and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007, Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson is the former Chairman of Tranzyme Pharma, Inc. Mr. Johnson currently serves as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation, Portola Pharmaceuticals, Inc. and Sucampo Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. Mr. Johnson holds a B.S. from the East Stroudsburg University of Pennsylvania.

Matthew Pauls

Mr. Matthew Pauls is Chief Executive Officer, Director of the company. since August 2014 and as a member of our board of directors since September 2015. Prior to joining Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded biopharmaceutical company, from April 2013 to August 2014. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, a publicly traded specialty biopharmaceutical company, beginning in 2007 until March 2013, most recently as Senior Vice President, Head of Global Commercial Operations. Mr. Pauls also held positions at Bristol-Myers Squibb, a publicly traded pharmaceutical company, in Brand Management and Payor Marketing, and at Johnson & Johnson, a publicly traded medical devices, pharmaceutical and consumer packaged goods manufacturer, in various U.S. and global commercial roles. He is a volunteer board member of the Pennington School in Pennington, New Jersey, and the Boys & Girls Clubs of Philadelphia. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

A. Davis

Mr. A. Brian Davis is Chief Financial Officer of the company. since March 2015. Prior to joining Strongbridge, Mr. Davis served as Senior Vice President and Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company, from August 2010 to December 2014. In December 2014, Tengion, Inc. filed a petition for relief under Chapter 7 of Title 11 of the United States Bankruptcy Code. From 2009 to July 2010, Mr. Davis served in a consulting capacity as Chief Financial Officer of Neose Technologies, Inc., a biopharmaceutical company. Mr. Davis worked at Neose Technologies, Inc. from 1994 to 2009, where he held several positions of increasing responsibility, including Senior Vice President and Chief Financial Officer. Mr. Davis is licensed as a certified public accountant, and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School at the University of Pennsylvania.

Stephen Long

Mr. Stephen J. Long is Chief Legal Officer of the company. since March 2015. Prior to joining Strongbridge, Mr. Long served as Counsel at the law firm of Reed Smith LLP, from April 2013 to February 2015. He previously served at C.R. Bard, Inc., a medical device manufacturing company, from October 2000 to May 2012 in the roles of Vice President, General Counsel, as Vice President, and Secretary, and as Associate General Counsel. Mr. Long also served as Assistant General Counsel, Consumer Healthcare, at Warner-Lambert Company, and as Counsel for the company's pharmaceutical division from February 1998 to September 2000. Mr. Long held positions earlier in his career at the law firm of Willkie Farr & Gallagher and Bankers Trust Company. Mr. Long received his B.S. from the School of Industrial and Labor Relations at Cornell University and his J.D. from Albany Law School of Union University.

Robert Lutz

Mr. Robert Lutz is Chief Business Officer of the company. since October 2014. Prior to joining Strongbridge, he worked as a full-time consultant at Medgenics, a publicly traded, early-stage, gene-therapy and rare disease biotech company, from May 2014 to September 2014. Mr. Lutz worked at Shire Pharmaceuticals, a publicly traded specialty biopharmaceutical company, from November 2012 to April 2014, where he most recently served as Vice President and held key leadership positions in the Neurosciences Business unit. Prior to Shire Pharmaceuticals, Mr. Lutz worked in a variety of roles, including Vice President and Senior Associate, for Cinergy Corp., an electric and gas utility company. Mr. Lutz worked as a Senior Analyst at Alan B. Slifka and Co., a hedge fund, after having started his career at Goldman Sachs, where he served as a Financial Analyst in their principal investment area. He holds a B.A. in economics and computer science from Amherst College and an M.B.A. from the Kellogg School of Management.

Ruth Thieroff-Ekerdt

Dr. Ruth Thieroff-Ekerdt is Chief Medical Officer of the company. Since December 2014. Prior to joining Strongbridge, Dr. Thieroff-Ekerdt was Chief Medical Officer at Aptalis Pharmaceuticals, a pharmaceutical company, from February 2011 to February 2014. Aptalis Pharmaceuticals was acquired in February 2014 by Forest Laboratories. Aptalis Pharmaceuticals was formed in 2011 after the acquisition of Eurand Pharmaceuticals, a specialty pharmaceutical company focused on gastrointestinal diseases, where Dr. Thieroff-Ekerdt served as Chief Medical Officer beginning in 2008 until January 2011. Prior to that, Dr. Thieroff-Ekerdt held positions of increasing leadership in clinical and research functions at Bayer Consumer Care and Bayer Schering Pharmaceuticals (formerly Berlex Inc. and Schering AG). Dr. Thieroff-Ekerdt received her M.D. as well as a Dr. med degree from the Free University Berlin in Germany. She has additional training in pharmacology and toxicology, including training in clinical pharmacology.

Richard Kollender

Mr. Richard S. Kollender is Director of the company. since March 2015. Since January 2011, he has served as a Partner and Executive Manager of Quaker Partners Management, LP, a healthcare investment firm, which he initially joined in 2003, and was promoted to Partner in 2005. Mr. Kollender serves as a director of Celator Pharmaceuticals, Inc., Rapid Micro BioSystems and Tarsa Therapeutics. Mr. Kollender previously served as a director of Insmed, Inc., Transave, Inc., Nupathe, Inc., TargetRx, Inc., Precision Therapeutics, Inc., Transport Pharmaceuticals, Inc., and Corridor Pharmaceuticals. Mr. Kollender also held positions in sales, marketing and worldwide business development at GlaxoSmithKline, or GSK, and served as investment manager at S.R. One, the corporate venture capital arm of GSK. Mr. Kollender holds a B.A. in accounting from Franklin and Marshall College and practiced as a Certified Public Accountant for six years in public accounting at firms including KPMG.

Garheng Kong

Dr. Garheng Kong, M.D. Ph.D. is Director of the company. since September 2015. In July 2013, he founded, and has since served as managing partner of, HealthQuest Capital, a healthcare venture growth fund focused on medical products, devices, diagnostics, consumer health and healthcare IT. Dr. Kong was a general partner at Sofinnova Ventures, a venture firm focused on life sciences, from September 2010 to December 2013. From May 2000 to September 2010, he worked at Intersouth Partners, a venture capital firm, serving most recently as a general partner. Dr. Kong currently serves as a director of Cempra, Inc., Histogenics Corporation, Alimera Sciences, Inc. and Laboratory Corporation of America Holdings. Dr. Kong holds a B.S. from Stanford University and an M.D., Ph.D. and M.B.A. from Duke University.

Marten Steen

Dr. Marten Steen is Director of the company. since December 2014. Since April 2010, he has served as a Partner of HealthCap VI LP, a venture capital firm investing in life science companies. Prior to HealthCap, from February 2008 until March 2010, Dr. Steen served as director at Merck Serono SA, a biopharmaceutical company. Currently, he serves as a member of the board of directors of Wilson Therapeutics AB, Vaxin Inc. and BioClin Therapeutics Inc. He previously served on the boards of Ultragenyx Inc. and FerroKin Biosciences. Dr. Steen holds a B.Sc. in Business Administration, an M.D., and a Ph.D. in Clinical Chemistry, all from Lund University.

Hilde Steineger

Dr. Hilde H. Steineger, Ph.D. is Director of the company. since January 2014. She is currently Head of Innovation Management in the Nutrition & Health Division of BASF. She previously served as the Head of Global Omega-3 Innovation Management at Pronova BioPharma ASA, a BASF company, from April 2013 to May 2015. From August 2007 to June 2010, Dr. Steineger was Head of Investor Relations for Pronova BioPharma and Vice President Business Development in Pronova BioPharma from November 2009 to April 2013. Dr. Steineger is a board member and Head of the Audit Committee of Nordic Nanovector ASA. Dr. Steineger also serves as a director of PCI Biotech AS and Afiew AS. She previously served as a member of the board of directors of Algeta ASA, Weifa AS, Invent2 AS, Alertis AS, Clavis ASA and Biotech Pharmacon ASA. Dr. Steineger holds a Ph.D. in medical biochemistry from University of Oslo.

Basic Compensation